tradingkey.logo

Vivos Therapeutics Inc

VVOS
1.970USD
-0.010-0.51%
收盘 12/19, 16:00美东报价延迟15分钟
16.29M总市值
亏损市盈率 TTM

Vivos Therapeutics Inc

1.970
-0.010-0.51%

关于 Vivos Therapeutics Inc 公司

Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing diagnostic and treatment methods that promote sleep wellness and health for patients suffering from breathing and sleep issues such as obstructive sleep apnea (OSA) and snoring in adults. The Company's Complete Airway Repositioning and/or Expansion (CARE) devices are the oral appliances cleared by the United States Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA (including severe OSA) and moderate-to-severe OSA in children ages 6 to 17 within the FDA cleared usage for such devices. The Company's products and services include Vivos CARE oral appliance therapy, Vivos oral appliances and therapies outside of CARE system, Vivos AireO2, Adjunctive Treatment, Treatment Navigator, Vivos Billing Intelligence Service (BIS) and Vivos Airway Intelligence Service, and others. The Company has sleep testing centers and associated medical sleep practice.

Vivos Therapeutics Inc简介

公司代码VVOS
公司名称Vivos Therapeutics Inc
上市日期Dec 11, 2020
CEOHuntsman (R. Kirk)
员工数量109
证券类型Ordinary Share
年结日Dec 11
公司地址7921 Southpark Plaza,
城市LITTLETON
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编80120
电话18669084867
网址https://vivos.com/
公司代码VVOS
上市日期Dec 11, 2020
CEOHuntsman (R. Kirk)

Vivos Therapeutics Inc公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Bradford K. (Brad) Amman
Mr. Bradford K. (Brad) Amman
Chief Financial Officer
Chief Financial Officer
80.00
--
Mr. R. Kirk Huntsman
Mr. R. Kirk Huntsman
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Ralph E. Green, DDS
Dr. Ralph E. Green, DDS
Independent Director
Independent Director
--
--
Ms. Anja B. Krammer
Ms. Anja B. Krammer
Independent Director
Independent Director
--
--
Mr. Mark F. Lindsay
Mr. Mark F. Lindsay
Independent Director
Independent Director
--
--
Dr. Matthew Thompson, M.D.
Dr. Matthew Thompson, M.D.
Independent Director
Independent Director
--
--
Mr. Leonard J. (Lenny) Sokolow, CPA
Mr. Leonard J. (Lenny) Sokolow, CPA
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Bradford K. (Brad) Amman
Mr. Bradford K. (Brad) Amman
Chief Financial Officer
Chief Financial Officer
80.00
--
Mr. R. Kirk Huntsman
Mr. R. Kirk Huntsman
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Ralph E. Green, DDS
Dr. Ralph E. Green, DDS
Independent Director
Independent Director
--
--
Ms. Anja B. Krammer
Ms. Anja B. Krammer
Independent Director
Independent Director
--
--
Mr. Mark F. Lindsay
Mr. Mark F. Lindsay
Independent Director
Independent Director
--
--
Dr. Matthew Thompson, M.D.
Dr. Matthew Thompson, M.D.
Independent Director
Independent Director
--
--

收入明细

单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
业务USD
名称
营收
占比
Appliance sales to integrated providers
1.03M
26.91%
Center revenue
857.00K
22.43%
Sleep testing services
844.00K
22.09%
Sponsorship/seminar
608.00K
15.92%
Billing intelligence service
190.00K
4.97%
其他
293.00K
7.67%
由于公司未披露,未能获取相关数据
业务
地区
业务USD
名称
营收
占比
Appliance sales to integrated providers
1.03M
26.91%
Center revenue
857.00K
22.43%
Sleep testing services
844.00K
22.09%
Sponsorship/seminar
608.00K
15.92%
Billing intelligence service
190.00K
4.97%
其他
293.00K
7.67%

股东统计

更新时间: 11月18日 周二
更新时间: 11月18日 周二
持股股东
股东类型
持股股东
持股股东
占比
Skaff (Michael C.)
9.21%
Luo (Dawei)
6.36%
V-CO Investors, L.L.C.
5.72%
Armistice Capital LLC
2.78%
Intracoastal Capital, L.L.C.
2.54%
其他
73.37%
持股股东
持股股东
占比
Skaff (Michael C.)
9.21%
Luo (Dawei)
6.36%
V-CO Investors, L.L.C.
5.72%
Armistice Capital LLC
2.78%
Intracoastal Capital, L.L.C.
2.54%
其他
73.37%
股东类型
持股股东
占比
Individual Investor
16.39%
Corporation
8.27%
Hedge Fund
5.48%
Investment Advisor
4.48%
Investment Advisor/Hedge Fund
1.08%
Venture Capital
0.92%
其他
63.38%

机构持股

更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
53
815.76K
10.87%
-21.74K
2025Q2
60
2.22M
33.10%
+944.35K
2025Q1
65
1.44M
22.49%
+733.38K
2024Q4
63
1.28M
22.00%
+869.59K
2024Q3
68
786.28K
18.32%
+305.75K
2024Q2
66
387.48K
12.85%
-179.65K
2024Q1
67
465.07K
19.33%
-62.17K
2023Q4
69
458.43K
25.00%
-105.78K
2023Q3
76
380.33K
31.77%
-57.99K
2023Q2
78
390.56K
32.63%
-94.20K
查看更多

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
Skaff (Michael C.)
828.00K
11.03%
+828.00K
--
Jun 09, 2025
Luo (Dawei)
572.02K
7.62%
+572.02K
--
Jul 08, 2025
V-CO Investors, L.L.C.
514.50K
6.86%
--
--
Jun 09, 2025
Armistice Capital LLC
250.28K
3.33%
+250.28K
--
Sep 30, 2024
Intracoastal Capital, L.L.C.
228.61K
3.05%
+228.61K
--
Dec 30, 2024
The Vanguard Group, Inc.
42.63K
0.57%
--
--
Jun 30, 2025
Ionic Ventures LLC
83.00K
1.11%
+83.00K
--
Sep 30, 2024
Huntsman (Ronald Kirk)
73.06K
0.97%
--
--
Sep 08, 2025
查看更多

持股ETF

更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
DFA Dimensional US Sustainability Core 1 ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
占比0%

分红派息

近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据

拆合股

公告日期
类型
比率
Oct 26, 2023
Merger
25→1
Oct 26, 2023
Merger
25→1
Oct 26, 2023
Merger
25→1
Oct 26, 2023
Merger
25→1
公告日期
类型
比率
Oct 26, 2023
Merger
25→1
Oct 26, 2023
Merger
25→1
Oct 26, 2023
Merger
25→1
Oct 26, 2023
Merger
25→1

常见问题

Vivos Therapeutics Inc的前五大股东是谁?

Vivos Therapeutics Inc 的前五大股东如下:
Skaff (Michael C.)持有股份:828.00K,占总股份比例:11.03%。
Luo (Dawei)持有股份:572.02K,占总股份比例:7.62%。
V-CO Investors, L.L.C.持有股份:514.50K,占总股份比例:6.86%。
Armistice Capital LLC持有股份:250.28K,占总股份比例:3.33%。
Intracoastal Capital, L.L.C.持有股份:228.61K,占总股份比例:3.05%。

Vivos Therapeutics Inc的前三大股东类型是什么?

Vivos Therapeutics Inc 的前三大股东类型分别是:
Skaff (Michael C.)
Luo (Dawei)
V-CO Investors, L.L.C.

有多少机构持有Vivos Therapeutics Inc(VVOS)的股份?

截至2025Q3,共有53家机构持有Vivos Therapeutics Inc的股份,合计持有的股份价值约为815.76K,占公司总股份的10.87%。与2025Q2相比,机构持股有所增加,增幅为-22.23%。

哪个业务部门对Vivos Therapeutics Inc的收入贡献最大?

在FY2025Q2,Appliance sales to integrated providers业务部门对Vivos Therapeutics Inc的收入贡献最大,创收1.03M,占总收入的26.91%。
KeyAI